-
Panel examines measures of behavioral markers for diabetes self-management
Various self-assessment tools exist to help patients with diabetes monitor their daily activities and provide their care teams with insights into glucose levels. Methods for tracking behavioral markers include sleep monitoring and actigraphy devices to track physical activity. Soohyun Nam, PhD, APRN, ANP-BC, FAHA, FAAN, discussed ecological momentary assessments.
-
Researchers weigh in on dietary management options
Dietary choices are crucial for managing type 2 diabetes. Experts including Roy Taylor, MD, shared their perspectives on nutrition programs that have helped patients reduce or manage type 2 diabetes while also living healthier lives. These programs incorporate low-calorie diets, low-carb diets, and glycemic excursion minimization.
-
First phase 3 results for high-dose oral semaglutide to be released in San Diego
Vanita R. Aroda, MD, will share results from two trials, OASIS 1 and PIONEER PLUS, and discuss the effectiveness of higher dose semaglutide in treating patients with type 2 diabetes as well as patients with obesity without type 2 diabetes. She will discuss how a high-dose semaglutide regimen can help patients reach their health goals.
-
Investigators to trace ongoing impact of DCCT/EDIC trial results in treating type 1 diabetes
Forty years after the launch of the Diabetes Control and Complications Trial, the Epidemiology of Diabetes Interventions and Complications study continues to observe and report on 1,000 patients. Gayle Lorenzi, RN, CDCES, who manages the San Diego DCCT/EDIC site, and other investigators will discuss how the data gleaned from this sustained research has transformed management…
-
Experts will discuss beta-cell identity across the lifespan
Raphael Scharfmann, PhD, will provide insight on the earliest beta cells: fetal pancreatic beta cells. His focus will be on the human fetal pancreas and what it can reveal about beta-cell identity. Other panelists will discuss postnatal beta cells and beta-cell aging.